Guja C, et al. - Researchers undertook a comparative examination of the efficacy and safety of adding the glucagon-like peptide-1 receptor agonist exenatide once weekly (QW) 2 mg or placebo among patients with type 2 diabetes inadequately controlled despite titrated insulin glargine (IG) ± metformin. The inference drawn was that exenatide QW notably improved glucose control and decreased body weight. No reports of increased hypoglycaemia or unexpected safety findings were found.